Abd El Aziz Mohamed A, Facciorusso Antonio, Nayfeh Tarek, Saadi Samer, Elnaggar Mohamed, Cotsoglou Christian, Sacco Rodolfo
Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Gastroenterology Unit, Department of Medical Sciences, Ospedali Riuniti di Foggia, 71122 Foggia, Italy.
Vaccines (Basel). 2020 Oct 19;8(4):616. doi: 10.3390/vaccines8040616.
Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC.
尽管在筛查方案和治疗选择方面取得了进展，但肝细胞癌（HCC）仍被认为是肝硬化患者中最致命的恶性肿瘤。此外，不可切除HCC一线治疗失败后的生存结果仍然很差，治疗选择有限。其中一种选择是免疫检查点抑制剂。本研究的目的是全面综述免疫检查点抑制剂对HCC患者的疗效和安全性。
Zotero 插件
